January 2024 - Cancer Currents Blog
-
What Happens If More People Get Screened for Cancer?Researchers used computer modeling to estimate the number of deaths that could be prevented, and the harms caused, if more people used USPSTF-recommended cancer screening tests. The study’s lead investigator, Dr. Amy Knudsen, explains the findings.
-
Can Some People with Breast Cancer Safely Skip Lymph Node Radiation?Some people with no evidence of cancer in nearby lymph nodes after presurgical chemotherapy can skip radiation to that area without increasing the risk of the cancer returning, a clinical trial found. But some experts caution that more details are needed.
-
Trial Results Support Adding Daratumumab to Initial Treatment for Multiple MyelomaAdding daratumumab (Darzalex) to standard treatment helped people with newly diagnosed multiple myeloma live longer without their cancer getting worse or dying. People taking daratumumab were also more likely to have no detectable signs of cancer (minimal residual disease) after treatment.
-
For People with Inherited Risk of Stomach Cancer, Gastrectomy Has Lasting ConsequencesIn a recent study, more than 90% of people who’d had their stomach surgically removed to prevent cancer experienced a least one chronic complication 2 years out from their surgery. For some, the complications are life altering.
-
Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t SpreadUnder a new FDA approval, enzalutamide (Xtandi) can now be used alone, or in combination with leuprolide, to treat people with nonmetastatic prostate cancer that is at high risk of returning after surgery or radiation.
-
Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal CancerFDA approved toripalimab (Loqtorzi) based on the results of a large clinical trial showing that, when added to chemotherapy, the drug extended survival in people with nasopharyngeal cancer that returned after initial treatment or spread in the body.